Genmab

Genmab A/S
Company typePublic
Nasdaq Copenhagen: GMAB
Nasdaq: GMAB (ADR)
OMX Copenhagen 25 component[1]
IndustryBiotechnology
Founded1999; 26 years ago (1999)
FounderFlorian Schönharting[2][3][4] and Lisa Drakeman[5]
HeadquartersCopenhagen, Denmark
Number of locations
4 (2023)[6]
Key people
ProductsDARZALEX/
DARZALEX FASPRO
EPKINLY/TEPKINLY
Kesimpta
RYBREVANT
TALVEY
TECVAYLI
TEPEZZA
Tivdak
RevenueDKK 16.474 billion (2023)[6]
DKK 5.321 billion (2023)[6]
DKK 4.352 billion (2023)[6]
Number of employees
2,204 (2023)[6]
WebsiteGenmab.com

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.[7] The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark[8] and the NASDAQ Global Select Market in the US.[9]

Technology

Genmab's technology is licensed from Medarex to create fully human high affinity antibodies using transgenic mice. These antibodies are less likely to elicit an allergic reaction and other side effects compared with other types of man-made antibodies containing other animal proteins because the IgG antibodies produced have human proteins. This technology is called the HuMab-Mouse technology. One benefit of using this type of technology is that there is no need for humanization or complicated genetic engineering to make this antibody fit for humans which cuts down on expenses and time spent developing it. It can be generated within months and can be selected to bind to specific antigens such as tumor cells and other infectious agents.

Genmab also has developed its own technology called UniBody, which is used to make smaller antibodies in contrast to the traditional full sized monoclonal antibody. Its smaller size allows for better distribution over larger target areas like tumors. The UniBody can only bind to one site and doesn’t elicit a harmful immune response by binding to two sites and over-activating cell growth. It does not kill target cells but rather silences or inhibits them. Thus it can be used to treat certain cancers, inflammations, allergies and asthmas, where killing the cell isn’t the objective.[10]

The technology modifies the human IgG4 antibody. Normally the IgG4 is considered inert and doesn’t elicit an immune response. However, they are also unstable and fall apart easily, which makes them unsuitable for therapeutic use. Genmab changes the shape of the IgG4 antibody by eliminating the hinge, the part of the antibody that creates the “Y” shape. This halves the antibody, creating a smaller version now known as their UniBody. This smaller version can only bind to one site and does not stimulate cancer cells to grow.[11]

History

Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999. Danish investment firm BankInvest, under Florian Schönharting, provided the seed investment for the company to start up in Copenhagen. Like Medarex, Genmab began work producing monoclonal antibodies for life-threatening or debilitating diseases. Rising quickly in the Biotech world, Genmab attracted many investors, especially venture capital firms. The company went public in October 2000, earning DKK 1.56 billion, and had a second public offering in January 2006, yielding DKK 800 million.

The company's initial R&D location was a nine-story building in Utrecht Science Park, in the Netherlands; this was replaced with an "R&D Center" also in Utrecht, in June 2018.[5] By mid-2019, this new facility was at capacity, and plans were set afoot to build an adjacent, connected facility.[5]

By 2001, Medarex and Genmab had come back together in a drug development partnership, which highlighted the manufacturing deficit and clinical development expertise of Genmab relative to Medarex.[12]

In 2005, the Biotechnology Industry Organization (BIO) and the Long Island Life Sciences Initiative honored Genmab with a James D. Watson Helix Award.[13]

2008 saw the company purchasing a 22,000-litre, 36-acre antibody manufacturing plant in Brooklyn Park, Minnesota from PDL BioPharma, with plans to retain all 170 employees thereat.[5][14] However, the company ran into financial trouble originating from several quarters, and a decision to sell the facility was reached in late 2009, after Genmab had started producing development scale batches from the facility.[5] In 2008, the world was experiencing a financial crisis as a whole, and GlaxoSmithKline decided to exit oncology, which impacted co-development of ofatumumab, an oncology-directed product.[5] In tandem with the sale of the plant, the company reorganized and planned to dismiss about 300 employees.[5] Selling the facility, though, proved very difficult, due in large part to the global financial crisis; by 2012, Genmab had decided to simply write-off the entire facility from the company's balance sheets.[5] A sale of the facility to Baxter came in February 2013.[5]

Following the failed strategy of in-housing manufacturing, Genmab chose to thereafter completely outsource both manufacturing and the conduct of clinical trials.[5]

The Company's first product, Arzerra (ofatumumab) reached the US market in 2009 for refractory chronic lymphocytic leukemia.[15][failed verification]

Executive history

Lisa N. Drakeman, Ph.D. had been a vice president at Medarex and wife of Donald Drakeman, Medarex's CEO and President at the time. Drakeman was one of Genmab's co-founders and was appointed chief executive officer (CEO) of the company upon incorporation in 1999, also joining the board of directors.[5] As of 2002, Drakeman remained in the CEO role,[16] but by 2010 she had announced her retirement.[5]

In 2010, Jan Van de Winkel, a co-founder of the firm, was appointed as President and CEO of Genmab.[5] Since the company started in 1999, he had been Genmab's chief scientific officer (CSO); he had concurrently served as head of research, then president of R&D.[5] As of 2019, Van de Winkel remained CEO of the firm.[5] Van de Winkel is a scientist, having produced more than 300 publications during his career.[5]

Partnerships

Amgen: In May 1999, Genmab entered a sub-license agreement with Amgen where it would gain rights to the IL15 antibodies. In October 2001, this was replaced by a direct license agreement where Amgen retained exclusive commercialization options for the products through phase II. Amgen has also expanded its agreement to a new antibody program targeting additional disease targets. Amgen has discontinued development of the IL15 antibody, AMG 714, in psoriasis and rheumatoid arthritis based on disappointing results from recent clinical studies. Amgen is exploring options to maximize the value of this asset, but as this time, no further internal development of a lead indication is planned.

GlaxoSmithKline: In December 2006, Genmab entered a deal with GlaxoSmithKline to co-develop and commercialize ofatumumab,[17] a drug that could be used for treatment in CD20 positive B-cell chronic lymphocytic leukemia, follicular non-Hodgkin’s lymphoma, rheumatoid arthritis and other indications. The agreement gave Genmab a license fee of DKK 582 million (US$102 million) and GSK bought 4,471,202 shares of Genmab for DKK 2,033 million (US$359 million). The potential value of this agreement could be DKK 12.0 billion (US$2.1 billion) if all milestones are reached and commercial success is reached in the fields of cancer, autoimmune, and inflammatory disease.[17] The intention of GlaxoSmithKline to exit oncology, disagreement around milestones reached, and financial difficulties of Genmab, led to re-negotiation of the partnership in mid-2010, resulting in an immediate US$135 million payment by GlaxoSmithKline and future financial and licensing concessions on the part of Genmab.[5]

In addition, Genmab has collaborations with Roche (RG1507, a monoclonal antibody directed against IGF-1R, collaboration was terminated in 2009)[18]

In April 2024, the company announced it would acquire ProfoundBio for $1.8 billion.[19]

Products

The company has 8 approved antibodies (monoclonal and bispecific) used in 8 marketed products, covering cancer indications and autoimmune diseases.[6]

Proprietary, marketed with partners:

Marketed by partners:

Furthermore both Genmab and its partners have a whole range of antibody programs, building on Genmab technologies, in clinical and pre-clinical development in both cancer and autoimmune diseases.
Genmab have several late stage clinical programs for tisotumab vedotin (cervical cancer, ovarian cancer and solid tumors) and epcoritamab (B-cell non-Hodgkin lymphoma and Relapsed/refractory Follicular lymphoma).
The partners have, among others, clinical programs for daratumumab (non-MM blood cancers), amivantamab (gastric cancer and esophageal cancer), Mim8 (Factor VIII mimetic bi-specific antibody) (Haemophilia A), inclacumab (VOC in Sickle cell disease) and teprotumumab (diffuse cutaneous systemic sclerosis).[citation needed]

Pipeline

Proprietary Products

Approved Medicines/Products

Approved Product Target Developed by Disease indications Approval Year
EPKINLY/TEPKINLY (epcoritamab) CD3, CD20 50:50 Genmab/AbbVie Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) 2023[20]
Tivdak (tisotumab vedotin) TF 50:50 Genmab/Seagen Recurrent or metastatic Cervical cancer 2021

Pipeline, Including Further Development for Approved Medicines

Product Target Developed by Disease indications Most Advanced Development Phase
Epcoritamab CD3, CD20 50:50 Genmab/AbbVie Relapsed/refractory DLBCL III
" " " Relapsed/refractory Follicular lymphoma (FL) III
" " " First line DLBCL III
" " " B-cell non-Hodgkin lymphoma (B-NHL) II
" " " Relapsed/refractory chronic lymphocytic leukemia (CLL) & Richter's syndrome I/II
" " " Indolent NHL, pediatric patients I
Tisotumab vedotin TF 50:50 Genmab/Seagen Cervical cancer III
" " " Solid tumors II
Acasunlimab
(GEN1046/BNT311)		 PD-L1, 4-1BB 50:50 Genmab/BioNTech Non-small-cell lung cancer (NSCLC) II
" " " Advanced endometrial cancer II
" " " Solid tumors I/II
Tecaginlimab
(GEN1042/BNT312)		 CD40, 4-1BB " Solid tumors II
HexaBody-CD38
(GEN3014)		 CD38 Genmab (under an exclusive worldwide license/option agreement with Janssen) Hematologic malignancies II
DuoBody-CD3xB7H4
(GEN1047)		 CD3, B7H4 Genmab Solid tumors II
HexaBody-CD27
(GEN1053/BNT313)		 CD27 50:50 Genmab/BioNTech Solid tumors I
GEN1056
(BNT322)		 Undisclosed " Solid tumors I
DuoBody-CD3xCD20
GEN3017		 CD3, CD20 Genmab Relapsed/refractory Hodgkin lymphoma (HL) & NHL I

Programs Incorporating Genmab’s Innovation and Technology

Approved Medicines/Products

Approved Product Target Discovered and/or Developed & Marketed By Disease indications Approval Year Royalties
DARZALEX (iv) (daratumumab) and DARZALEX FASPRO (subcu.) (daratumumab and hyaluronidase) CD38 Janssen Multiple myeloma (MM) 2015 (iv), 2020 (sc) 0-$3bn tiered: 14.92% (avg.), >$3bn fixed: 20%
DARZALEX FASPRO CD38 Janssen AL Amyloidosis 2021 As for MM
Kesimpta (ofatumumab) CD20 Novartis Relapsing remitting multiple sclerosis (RRMS) 2020 10%
TEPEZZA (teprotumumab) IGF-1R Amgen
(under sublicense from Roche)		 Thyroid eye disease (TED) 2020 6% (Jan Van de Winkel[21])
RYBREVANT (amivantamab) EGFR, cMet Janssen NSCLC 2021 8-10%
TECVAYLI (teclistamab) BCMA, CD3 Janssen Relapsed/refractory MM (RRMM) 2022 ~5-6%
TALVEY (talquetamab) GPRC5D, CD3 Janssen RRMM 2023 ~5-6%

Pipeline, Partner-owned products incorporating Genmab’s innovation, ≥Phase 2 Development

Product Target Discovered and/or Developed & Marketed By Disease indications Most Advanced Development Phase Royalties
Amivantamab EGFR, cMet Janssen Advanced or Metastatic Gastric or Esophageal cancer II 8-10%
Amivantamab " " Hepatocellular carcinoma II "
Amivantamab " " Advanced or metastatic colorectal cancer I/II "
Inclacumab selectin P Pfizer VOC in Sickle cell disease III
Est. prim. completion 2023-12		 5-6% (Jan Van de Winkel: "mid single-digit"[21])
Mim8
(Factor VIII mimetic bispecific antibody)		 FIXa, FX Novo Nordisk Haemophilia A III
Est. prim. completion 2024-05		 5-6% (Jan Van de Winkel: "mid single-digit"[21])
Camidanlumab tesirine
(ADCT-301)		 CD25 ADC Therapeutics Relapsed/refractory HL II
2022-11: FDA has advised ADCT that an ongoing ph3 study - preferably with full enrollment - is needed to support a BLA submission. ADCT therefore plans to conduct a ph3 study for which full enrollment is estimated to take 2 years.[22]		 5-9% tiered (GMAB: "mid-to-high single-digit tiered")
Ordesekimab IL-15 Sanofi Gluten-free diet non-responsive Celiac disease II -
Lu AF82422 Alpha-Synuclein Lundbeck Multiple system atrophy (MSA) II -

[6]

References

  1. ^ "OMX Copenhagen 25 index info".
  2. ^ "Biotekstjerne spottede de gode forretninger". Berlingske. 20 October 2018. Retrieved 14 November 2020.
  3. ^ "Marketscreener". Marketscrenner. Marketscreener. Retrieved 14 November 2020.
  4. ^ "Forward Pharma Board Members". Forward Pharma. Retrieved 14 November 2020.
  5. ^ a b c d e f g h i j k l m n o p q Wright, Rob (December 30, 2019). "The 5-Step Strategy That Saved Genmab From A Dire Outlook". Life Science Leader. VertMarkets. Retrieved 6 January 2020.
  6. ^ a b c d e f g h "Rooted in Science, Inspired by Patients - 2023 Annual Report". GlobeNewswire. 14 February 2024. Retrieved 11 March 2024.
  7. ^ Form 8-K Current Report (Form 8-K). US Securities and Exchange Commission. March 5, 1999. Contacts. Retrieved 6 January 2020.
  8. ^ "GMAB, Genmab, (DK0010272202)" (Dynamic webpage). Nasdaq Nordic Ltd. Retrieved 9 March 2022. Market: Nasdaq Copenhagen
  9. ^ "Genmab A/S ADS (GMAB)" (Dynamic webpage). Nasdaq Inc. Retrieved 9 March 2022. Market: Nasdaq
  10. ^ "About Genmab". Genmab. Archived from the original on November 3, 2010. Retrieved 3 November 2010.[self-published source]
  11. ^ "Next Generation Technology". Science and Research. Genmab. Archived from the original on October 8, 2010. Retrieved 3 November 2010.[self-published source]
  12. ^ Staff (June 28, 2001). "Business Notes". Central Jersey Briefcase. Courier News. Vol. 119, no. 23. Bridgewater, New Jersey: Gannett. p. A11. Retrieved 6 January 2020 – via Newspapers.com.
  13. ^ Debbie, Strickland (February 24, 2005). "James D. Watson Helix Awards Honor Biotech's Top Performers" (Press release). Biotechnology Industry Organization. Archived from the original on December 13, 2010. Retrieved 17 January 2011.
  14. ^ "PDL Biopharma to sell antibody plant". Star Tribune. Vol. XXVI, no. 324. Minneapolis, Minnesota: The Star Tribune Company. Dow Jones News Service. February 22, 2008. p. D2. Retrieved 6 January 2020 – via Newspapers.com.
  15. ^ "2009 Annual Report". Genmed. Archived from the original on December 1, 2010. Retrieved 3 November 2010.[self-published source]
  16. ^ Staff (June 27, 2002). "Roche expands commitment to innovative advanced medicines". The Nutley Sun. Nutley, New Jersey: North Jersey Media Group. p. 10. Retrieved 6 January 2020 – via Newspapers.com.
  17. ^ a b "Glaxo buys stake in Genmab". The Boston Globe. Vol. 270, no. 173. Associated Press. December 20, 2006. p. D5. Retrieved 6 January 2020 – via Newspapers.com.
  18. ^ Carroll, John (7 December 2009). "Genmab shares slide after Roche dumps collaboration". FierceBiotech. Questex. Retrieved 6 January 2020.
  19. ^ "Novartis, Ono Latest to Announce Billion-Dollar M&A Deals".
  20. ^ "EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)" (Press release). globenewswire. 19 May 2023. Retrieved 20 May 2023.
  21. ^ a b c "Morgan Stanley 20th Annual Global Healthcare Conference". event.webcasts.com. 13 September 2022. Retrieved 14 September 2022.
  22. ^ "Confirmatory Phase 3 Trial Needed Prior to Camidanlumab Tesirine BLA Submission for Accelerated Approval Path, FDA Says". www.cancernetwork.com. 11 November 2022. Retrieved 11 December 2022.

Read other articles:

Jambore Pramuka Dunia ke-6

Jambore Dunia Pramuka ke-6 adalah pertemuan atau jambore yang diadakan di Moisson, Prancis pada 1947. Jambore ini seharusnya diadakan pada tahun 1941 di Prancis, tetapi karena adanya Perang Dunia ke-2, akhirnya diundur dan diadakan setelah Perang selesai, karenanya dinamakan Jamboree of Peace / Jambore Perdamaian. Jambore yang diikuti oleh 24.152 [1] orang pandu ini menunjukkan bahwa meskipun selama bertahun-tahun perang Gerakan Kepanduan masih kuat dan terus berkembang. Pada saat aca...

 

Badan Akreditasi Nasional Perguruan Tinggi

Badan Akreditasi Nasional Perguruan Tinggi BAN-PTGambaran umumDidirikan1994Dasar hukumUU No. 12 Tahun 2012 Pendidikan TinggiPermendikbud No. 59 Tahun 2012 Badan Akreditasi NasionalBidang tugasAkreditasi Perguruan TinggiDi bawah koordinasiKementerian Pendidikan, Kebudayaan, Riset, dan TeknologiKepala BAN-PTProf. Dr. Ir. Ari Purbayanto, M.Sc.Sekretaris UtamaProf. Tjokorde Walmiki Samadhi, ST., MT., Ph.D.Kantor pusatKantor Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi G...

 

Синелобый амазон

Синелобый амазон Научная классификация Домен:ЭукариотыЦарство:ЖивотныеПодцарство:ЭуметазоиБез ранга:Двусторонне-симметричныеБез ранга:ВторичноротыеТип:ХордовыеПодтип:ПозвоночныеИнфратип:ЧелюстноротыеНадкласс:ЧетвероногиеКлада:АмниотыКлада:ЗавропсидыКласс:Пт�...

Berita Hiburan Beijing

Berita Hiburan BeijingTipeKoran harianPenerbitGrup Harian BeijingDidirikan4 Januari 1981Pandangan politikKomunisme, Sosialisme dengan karakteristik TiongkokBahasaAksara Han (sederhana)Berhenti publikasi1 Januari 2018 Berita Hiburan Beijing (diterjemahkan dalam bahasa Inggris menjadi Beijing Star Daily[1]) merupakan koran komprehensif yang diterbitkan oleh Harian Beijing. Sebelumnya koran ini bernama Berita Drama dan Film yang didirikan oleh Asosiasi Sastra dan Seni Beijing pada 4 Janu...

 

Healthcare in Malawi

Healthcare in Malawi and its limited resources are inadequate to fully address factors plaguing the population, including infant mortality and the very high burden of diseases, especially HIV/AIDS, malaria and tuberculosis. Background David Gordon Memorial Hospital in LivingstoniaThis section possibly contains original research. Please improve it by verifying the claims made and adding inline citations. Statements consisting only of original research should be removed. (September 2016) (Learn...

 

Martinus Beijerinck

Dutch microbiologist (1851–1931) Beijerinck redirects here. For the lunar crater, see Beijerinck (crater). Martinus BeijerinckBorn16 March 1851 (1851-03-16)Amsterdam, NetherlandsDied1 January 1931 (1931-02) (aged 79)Gorssel, NetherlandsAlma materLeiden UniversityKnown forOne of the founders of virology, environmental microbiology and general microbiologyConceptual discovery of virus (tobacco mosaic virus)Enrichment cultureBiological nitrogen fixationSulfate-reducing bact...

List of people from Boston

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: List of people from Boston – news · newspapers · books · scholar · JSTOR (September 2012) (Learn how and when to remove this message) This is a list of people who were born in, residents of, or otherwise closely associated with the city of Boston, Massachusett...

 

Палеопропитеки

† Палеопропитеки Научная классификация Домен:ЭукариотыЦарство:ЖивотныеПодцарство:ЭуметазоиБез ранга:Двусторонне-симметричныеБез ранга:ВторичноротыеТип:ХордовыеПодтип:ПозвоночныеИнфратип:ЧелюстноротыеНадкласс:ЧетвероногиеКлада:АмниотыКлада:СинапсидыКласс:�...

 

约翰斯顿环礁

此條目可参照英語維基百科相應條目来扩充。 (2021年5月6日)若您熟悉来源语言和主题，请协助参考外语维基百科扩充条目。请勿直接提交机械翻译，也不要翻译不可靠、低品质内容。依版权协议，译文需在编辑摘要注明来源，或于讨论页顶部标记{{Translated page}}标签。 约翰斯顿环礁Kalama Atoll 美國本土外小島嶼 Johnston Atoll 旗幟颂歌：《星條旗》The Star-Spangled Banner約翰斯頓環礁�...

Philippines at the 2023 ASEAN Para Games

Sporting event delegationPhilippines at the2023 ASEAN Para GamesIPC codePHINPCParalympic Committee of the Philippinesin Phnom PenhCompetitors174 in 13 sportsFlag bearerAriel Joseph Alegarbes (Swimming)MedalsRanked 5th Gold 34 Silver 33 Bronze 49 Total 116 ASEAN Para Games appearances (overview) 2001 2003 2005 2008 2009 2011 2013 2015 2017 2022 2023 The Philippines competed at the 2023 ASEAN Para Games in Phnom Penh, Cambodia which ran from 3 to 9 June 2023. The delegation led by chef de ...

 

Queen Sirikit National Convention Centre MRT station

ศูนย์การประชุมแห่งชาติสิริกิติ์Queen Sirikit National Convention Centre  MRT General informationLocationKhlong Toei, Bangkok, ThailandOwned byMass Rapid Transit Authority of Thailand (MRTA)Operated byBangkok Expressway and Metro Public Company Limited (BEM)Line(s) MRT  MRT Blue LinePlatforms1 island platformTracks2ConstructionStructure typeUndergroundAccessibleYesOther informationStation codeBL23HistoryOpened3&#...

 

John Martyn

British musician (1948–2009) For other people named John Martyn, see John Martyn (disambiguation). John MartynOBEMartyn in 1978Background informationBirth nameIain David McGeachyBorn(1948-09-11)11 September 1948[1]New Malden, Surrey, EnglandDied29 January 2009(2009-01-29) (aged 60)Thomastown, IrelandGenresFolk blues, progressive folk, folk-rock, folk jazzOccupation(s)Musician, songwriterInstrument(s)Guitar, vocalsYears active1967–2009LabelsIsland, WEAWebsitejohnmartyn.comMusi...

Isle of Ely (UK Parliament constituency)

Parliamentary constituency in the United Kingdom, 1918–1983 Isle of ElyFormer County constituencyfor the House of CommonsCountyCambridgeshire1918–1983SeatsOneCreated fromWisbechNewmarket (part)Chesterton (part)Replaced byNE CambridgeshireSE Cambridgeshire Isle of Ely was a county constituency represented in the House of Commons of the Parliament of the United Kingdom, centred on the Isle of Ely in Cambridgeshire. Until its abolition in 1983, it elected one Member of Parliament (MP) by the...

 

Cinta RockStar

Cinta RockStarGenre Drama Roman PembuatScreenplay ProductionsSutradaraOdy C. HarahapPemeran Ariel Tatum Derby Romero Faby Marcelia Fandy Christian Adjie Pangestu Abdurrahman Arif Virnie Ismail Agung Hercules Indah Yofana Marissa Jeffryna Penggubah lagu temaMiszyLagu pembukaKamu Gak Rock N Roll oleh MiszyLagu penutupKamu Gak Rock N Roll oleh MiszyNegara asalIndonesiaBahasa asliBahasa IndonesiaJmlh. musim1Jmlh. episode28ProduksiPengaturan kameraMulti-cameraDurasi90 menitRumah produksiScreenpla...

 

Yevlakh

Stasiun Kereta Yevlakh Peta Azerbaijan menunjukan Yevlax sahar. Yevlakh (bahasa Azerbaijan: Yevlax) adalah kota di Azerbaijan, 265 km sebelah barat ibu kota Azerbaijan, Baku. Kota ini dikelilingi oleh rayon dengan nama yang sama. lbsPembagian administratif Azerbaijan Distrik Absheron Agdam Agdash Aghjabadi Agstafa Agsu Astara Babek Balakan Barda Beylagan Bilasuvar Dashkasan Fuzuli Gadabay Goranboy Goychay Goygol Hajigabul Imishli Ismayilli Jabrayil Jalilabad Julfa Kalbajar Kangarli Khach...

Makedonia Tengah

Letak Makedonia Tengah di Yunani Makedonia Tengah merupakan sebuah periperi yang terletak di Yunani bagian utara. Ibu kotanya ialah Thessaloniki. Periperi ini memiliki luas wilayah 18.811 km² dengan memiliki jumlah penduduk 1.931.870 jiwa (2005). Komunitas Ampelókipoi (Αμπελόκηποι) Evosmos (Εύοσμος) Kalamariá (Καλαμαριά) Kateríni (Κατερίνη) Políchni (Πολίχνη) Sérres (Σέρρες) Stavroúpoli (Σταυρούπολη) Sykiés (Συκιές)...

 

Communes of France

France territorial subdivision for municipalities For other uses, see Communal (disambiguation). This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article possibly contains original research. Please improve it by verifying the claims made and adding inline citations. Statements consisting only of original research should be removed. (January 2015) (Learn how and when to remove this mes...

 

Anthony Modeste

Anthony Modeste Informasi pribadiNama lengkap Anthony ModesteTanggal lahir 14 April 1988 (umur 36)Tempat lahir Cannes, PrancisTinggi 1,86 m (6 ft 1 in)[1]Posisi bermain PenyerangInformasi klubKlub saat ini 1899 HoffenheimNomor 27Karier junior2001–2003 Fréjus2003–2007 NiceKarier senior*Tahun Tim Tampil (Gol)2007–2010 Nice 42 (3)2009–2010 → Angers (pinjaman) 37 (20)2010–2013 Bordeaux 52 (13)2012 → Blackburn Rovers (pinjaman) 5 (0)2012–2013 → Basti...

Pandemia de COVID-19 na África

Ver artigo principal: Pandemia de COVID-19 por paísMais informações: Pandemia de COVID-19Este artigo ou seção pode conter informações desatualizadas. Se tem conhecimento sobre o tema abordado, edite a página e inclua as informações mais recentes, citando fontes fiáveis e independentes. —Encontre fontes: ABW  • CAPES  • Google (N • L • A) Pandemia de COVID-19 na África Pandemia de COVID-19 na ÁfricaIntensidade dos...

 

Lard

Semi-solid white pork fat product For other uses, see Lard (disambiguation). LardWet-rendered lard, from pork fatbackFat compositionSaturated fatsTotal saturated38–43%:Palmitic acid: 25–28%Stearic acid: 12–14%Myristic acid: 1%Unsaturated fatsTotal unsaturated56–62%Monounsaturated47–50%:Oleic acid: 44–47%Palmitoleic acid: 3%PolyunsaturatedLinoleic acid: 6–10%[1][2]PropertiesFood energy per 100 g (3.5 oz)3,770 kJ (900 kcal)Melting pointbackfat: ...